Synthesis and pharmacological evaluation of 1-[(1,2-diphenyl-1H-4-imidazolyl)methyl]-4-phenylpiperazines with clozapine-like mixed activities at dopamine D2, serotonin, and GABAA receptors

Journal of Medicinal Chemistry

Volumn 45, Issue 21, 2002, Pages 4655-4668

  Asproni, Battistina ^a   Pau, Amedeo ^a   Bitti, Mauro ^a   Melosu, Marilena ^a   Cerri, Riccardo ^a   Dazzi, Laura ^b   Seu, Emanuele ^b   Maciocco, Elisabetta ^b   Sanna, Enrico ^b   Busonero, Fabiol ^b   Talani, Giuseppe ^b   Pusceddu, Luca ^b   Altomare, Cosimo ^c   Trapani, Giuseppe ^c   Biggio, Giovanni ^b  

^a UNIVERSITY OF SASSARI   (Italy)

^b UNIVERSITY OF CAGLIARI   (Italy)

^c UNIVERSITY OF BARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1 (3 CHLOROPHENYL) 4 [(1,2 DIPHENYL 1H IMIDAZOL 4 YL)METHYL]PIPERAZINE; 1 (4 CHLOROPHENYL) 4 [(1,2 DIPHENYL 1H IMIDAZOL 4 YL)METHYL]PIPERAZINE; 1 [(1,2 DIPHENYL 1H 4 IMIDAZOLYL)METHYL] 4 (2 METHOXYPHENYL)PIPERAZINE; 4 AMINOBUTYRIC ACID A RECEPTOR; CLOZAPINE; DOPAMINE; DOPAMINE 2 RECEPTOR; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; RECEPTOR SUBTYPE; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG SELECTIVITY; DRUG SYNTHESIS; IC 50; MALE; NONHUMAN; PHYSICAL CHEMISTRY; PREFRONTAL CORTEX; RAT; RECEPTOR AFFINITY; STRUCTURE ACTIVITY RELATION; XENOPUS;

ANIMALS; CEREBRAL CORTEX; CHLORIDE CHANNELS; CLOZAPINE; DOPAMINE; DOPAMINE ANTAGONISTS; DRUG DESIGN; GABA ANTAGONISTS; HUMANS; IMIDAZOLES; OOCYTES; PIPERAZINES; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RADIOLIGAND ASSAY; RATS; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, DOPAMINE D2; RECEPTORS, GABA-A; RECEPTORS, SEROTONIN; RECEPTORS, SEROTONIN, 5-HT1; SEROTONIN ANTAGONISTS; XENOPUS LAEVIS;

EID: 0037057578     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm020848t     Document Type: Article

References (80)

1. Reynolds, G. P. Developments in the Drug Treatment of Schizophrenia. Trends Pharmacol. Sci. 1992, 13, 116-121.
2. Creese, I.; Burt, D. R.; Snyder, S. H. Dopamine Receptor Binding Predicts Clinical and Pharmacological Potencies of Antischizophrenic Drugs. Science 1976, 192, 481-483.
3. Seeman, P.; Van Tol, H. H. M. Dopamine Receptor Pharmacology. Trends Pharmacol. Sci. 1994, 15, 264-270.
4. Davis, K. L.; Kahn, R. S.; Ko, G.; Davidson, M. Dopamine in Schizophrenia: A Review and Reconceptualization. Am. J. Psychiatry 1991, 148, 1474-1486.
5. Seeman, P. Dopamine Receptors and the Dopamine Hypothesis of Schizophrenia. Synapse 1987, 1, 133-152.
6. Hippius, H. A Historical Perspective of Clozapine. J. Clin. Psychiatry 1999, 60 (Suppl. 12), 22-23.
7. Worrel, J. A.; Marken, P. A.; Beckman, S. E.; Ruehter, V. L. Atypical Antipsychotic Agents: A Critical Review. Am. J. Health Syst. Pharm. 2000, 57, 238-255.
8. Remington, G.; Kapur, S. Atypical Antipsychotics: Are Some More Atypical Than Others? Psychopharmacology 2000, 148, 3-15.
9. Ashby, C. R., Jr.; Wang, R. Y. Pharmacological Actions of the Atypical Antipsychotic Drug Clozapine: A Review. Synapse 1996, 24, 349-394.
10. 1A Receptors. J. Pharmacol. Exp. Ther. 2000, 295, 853-861.
11. A Receptors. Neurochem. Res. 1998, 23, 1283-1290.
12. Michel, F. J.; Trudeau, L.-E. Clozapine Inhibits Synaptic Transmission at GABAergic Synapses Established by Ventral Tegmental Area Neurones in Culture. Neuropharmacology 2000, 39, 1536-1543.
13. Carlsson, A.; Waters, N.; Holm-Waters, S.; Tedroff, J.; Nilsson, M.; Carlsson, M. L. Interaction Between Monoamines, Glutamate, and GABA in Schizophrenia: New Evidence. Annu. Rev. Toxicol. 2001, 41, 237-260.
14. 2-Adrenoceptor Antagonism in the Anticataleptic Properties of the Atypical Neuroleptic Agent, Clozapine, in the Rat. Br. J. Pharmacol. 1998, 124, 1550-1556.
15. Ossowska, K.; Wedzony, K.; Wolfarth, D. The Role of GABA Mechanisms in the Globus Pallidus in Mediating Catalepsy, Stereotypy and Locomotor Activity. Pharmacol. Biochem. Behav. 1984, 21, 825-831.
16. Mao, C. C.; Marco, E.; Revuelta, A.; Bertilsson, L.; Costa, E. The Turnover of γ-Aminobutyric Acid in the Nuclei of Telencephalon: Implications in the Pharmacology of Antipsychotics and of a Minor Tranquillizer. Biol. Psychiatry 1977, 12, 359-371.
17. Korpi, E. R.; Wong, G.; Luddens, H. Subtype Specificity of γ-Aminobutyric Acid Type A Receptor Antagonism by Clozapine. Naunyn Schmiedeberg's Arch. Pharmacol. 1995, 352, 365-373.
18. Mouithys-Mickalad, A.; Kauffmann, J. M.; Petit, C.; Bruhwyler, J.; Liao, Y.; Wikstrom, H.; Damas, J.; Delarge, J.; Deby-Dupont, G.; Geczy, J.; Liegeois, J. F. Electrooxidation Potential as a Tool in the Early Screening for New Safer Clozapine-like Analogues. J. Med. Chem. 2001, 44, 769-776.
19. (a) Kapur, S.; Remington, G. Atypical Antipsychotics: New Directions and New Challenges in the Treatment of Schizophrenia. Annu. Rev. Med. 2001, 52, 503-517.
20. (b) Stip, E. Novel Antipsychotics: Issues and Controversies. Typicality of Atypical Antipsychotics. J. Psychiatry Neurosci. 2000, 25, 137-153.
21. (c) Tallman, J. F. Development of Novel Antipsychotic Drugs. Brain Res. Brain Res. Rev. 2000, 31, 385-390.
22. (d) Moore, N. A. Behavioural Pharmacology of the New Generation of Antipsychotic Agents. Br. J. Psychiatry Suppl. 1999, 38, 5-11.
23. 2 pKi Values. J. Pharmacol. Exp. Ther. 1989, 251, 238-246.
24. 2 and Dopamine 2 Receptors. J. Pharmacol. Exp. Ther. 1993, 266, 1374-1384.
25. (a) Love, R. C.; Nelson, M. W. Pharmacology and Clinical Experience with Risperidone. Exp. Opin. Pharmacother. 2000, 1, 1441-1453.
26. 2 Dopamine Receptor Occupancy in the Living Human Brain: A PET Study with Risperidone. Psychopharmacology (Berlin) 1993, 110, 265-272.
27. (a) Bhana, N.; Foster, R. H.; Olney, R.; Plosker, G. L. Olanzapine: An Update Review of Its Use in the Management of Schizophrenia. Drugs 2001, 61, 111-161.
28. 2 Dopamine Receptor Occupancy Induced by Olanzapine in Healthy Subjects. Neuropsychopharmacology 1997, 16, 1-7.
29. (a) Brown, L. A.; Levin, G. M. Sertindole, A New Atypical Antipsychotic for the Treatment of Schizophrenia. Pharmacotherapy 1998, 18, 69-83.
30. (b) Kane, J. M. Sertindole: A Review of Clinical Efficacy. Int. Clin. Psychopharmacol. 1998, 13, S59-S63.
31. (a) Kasper, S.; Tauscher, J.; Heiden, A. Quetiapine: Efficacy and Tolerability in Schizophrenia. Eur. Neuropsychopharmacol. 2001, Suppl. 4, S405-413.
32. (b) Kasper, S.; Muller-Spahn, F. Review of Quetiapine and Its Clinical Applications in Schizophrenia. Exp. Opin. Pharmacother. 2000, 1, 783-801.
33. Gunasekara, N. S.; Spencer, C. M.; Keating, G. M. Ziprasidone: A Review of Its Use in Schizophrenia and Schizoaffective Disorder. Drugs 2002, 62, 1217-1251.
34. 1A Partial Agonists with Potential as Atypical Antipsychotic Agents. J. Med. Chem. 1999, 42, 3342-3355.
35. 1 Receptors. J. Med. Chem. 1998, 41, 1997-2009.
36. 2 Affinity as Potential Atypical Antipsychotics. J. Med. Chem. 1998, 41, 2010-2018.
37. 1A/D-2 Activity of a New Model of Arylpiperazines: 1-Aryl-4-[3-(1,2-dihydronaphthalen-4-yl)-n-propyl]piperazines. 1. Synthesis and Structure-Activity Relationships. J. Med. Chem. 1994, 37, 99-104.
38. 1A Receptor Ligands. J. Med. Chem. 1995, 38, 1942-1954.
39. (b) Lyon, R. A.; Titeler, M.; McKenney, J. D.; Magee, P. S.; Glennon, R. A. Synthesis and Evaluation of Phenyl- and Benzoylpiperazines as Potential Serotonergic Agents. J. Med. Chem. 1986, 29, 630-634.
40. (a) Harbert, C. A.; Plattner, J. J.; Welch, W. M.; Weissman, A.; Koe, B. K. Neuroleptic Activity in 5-Aryltetrahydro-γ-carbolines. J. Med. Chem. 1980, 23, 635-643.
41. (b) Abou-Gharbia, M. Biological Activity of Substituted γ-Carbolines. Drugs Future 1989, 14, 453-459.
42. Khanna, I. K.; Weier, R. M.; Yu, Y.; Xu, X. D.; Koszyk, F. J.; Collins, P. W.; Koboldt, C. M.; Veenhuizen, A. W.; Perkins, W. E.; Casler, J. J.; Mesferrer, J. L.; Zhang, Y. Y.; Gregory, S. A.; Seibert, K.; Isakson, P. C. 1,2-Diarylimidazoles as Potent, Cyclooxygenase-2 Selective, and Orally Active Antiinflammatory Agents. J. Med. Chem. 1997, 40, 1634-1647.
43. Brown, H. C.; Heim, P. Selective Reductions. XVIII. The Fast Reaction of Primary, Secondary, and Tertiary Amides with Diborane. A Simple, Convenient Procedure for the Conversion of Amides to the Corresponding Amines. J. Org. Chem. 1973, 38, 912-916.
44. HyperChem Program release 5.01 for Windows; Hypercube Inc., 1996).
45. Schmutz, J. Neuroleptic Pyperazinyl-dibenzo-azepines. Chemistry and Structure-Activity Relationships. Arzneim. Forsch. (Drug Res.) 1975, 25, 712-720.
46. Chakrabarti, J. K.; Hotten, T. M.; Morgan, S. E.; Pullar, I. A.; Rackham, D. M.; Risius, F. C.; Wedley, S.; Chaney, M. O.; Jones, N. D. Effects of Conformationally Restricted 4-Piperazinyl-10H-thienobenzodiazepine Neuroleptics on Central Dopaminergic and Cholinergic Systems. J. Med. Chem. 1982, 25, 1133-1140.
47. Lanig, H.; Utz, W.; Gmeiner, P. Comparative Molecular Field Analysis of Dopamine D4 Receptor Antagonists Including 3-[4-(4-Chlorophenyl)piperazin-1-ylmethyl]pyrazolo[1,5-a]pyridine (FAUC 113), 3-[4-(4-Chlorophenyl)piperazin-1-ylmethyl]-1H-pyrrolo-[2,3-b]pyridine (L-745,870), and clozapine. J. Med. Chem. 2001, 44, 1151-1157.
48. 3H]YM-09151-2 Binding in the Rat Brain by Thioridazine, Risperidone and Clozapine, but Not by other Antipsychotics. Eur. J. Pharmacol. 1993, 237, 183-189.
49. (a) Hansch, C.; Leo, A. Substituent Constants for Correlation Analysis in Chemistry and Biology; John Wiley and Sons: New York, 1979.
50. (b) Hansch, C.; Leo, A. Exploring QSAR: Fundamentals and Applications in Chemistry and Biology; ACS Professional Reference Book; American Chemical Society: Washington, DC, 1995.
51. (c) van de Waterbeemd, H.; Testa, B. The Parametrization of Lipophilicity and Other Structural Properties in Drug Design. In Advances in Drug Research; Testa, B., Ed.; Academic Press: London, 1987; Vol. 16, pp 87-227.
52. a Prediction for Organic Acids and Bases; Chapman and Hall: London and New York, 1981; pp 137-138.
53. Williams, S. G.; Norrington, F. E. Determination of Positional Weighting Factors for the Swain and Lupton Substituent Constants F and R. J. Am. Chem. Soc. 1976, 98, 508-516.
54. CLOG P for Windows, Version 4.0; BioByte Corp.: Claremont, CA.
55. Tetko, I. V.; Tanchuk, V. Yu.; Kasheva, T. N.; Villa, A. E. P. Internet Software for Calculation of Lipophilicity and Aqueous Solubility of Chemical Compounds. J. Chem. Inf. Sci. 2001, 41, 246-252.
56. ACD/Labs package, release 5.0; Advanced Chemistry Development Inc.: Toronto, Ontario, Canada.
57. 2C Receptor Antagonists: Synthesis, Pharmacology, 3D-QSAR, and Molecular Modeling of (Aminoalkyl)benzo and Heterocycloalkanones. J. Med. Chem. 2002, 45, 54-71.
58. Höltje, H. D. Pharmacophore Identification and Receptor Mapping. In The Practice of the Medicinal Chemistry; Wermuth, C. G., Ed.; Academic Press Limited: New York, 1996; pp 437-457.
59. 1A Receptor: Contribution of the Molecular Lipophilicity Potential to Three-Dimensional Quantitative Structure-Affinity Relationship Models. J. Med. Chem. 1996, 39, 126-134.
60. Deutch, A. Y. The Regulation of Subcortical Dopamine Systems by the Prefrontal Cortex: Interactions of Central Dopamine Systems and the Pathogenesis of Schizophrenia. J. Neural Transm. (Gen. Sect.) (Suppl.) 1992, 36, 61-89.
61. Goldman-Rakic, P. S. Cerebral Cortical Mechanisms in Schizophrenia. Neuropsychopharmacology 1994, 10, 22S-27S.
62. Moghaddam, B.; Bunney, B. S. Utilization of Microdialysis for Assessing the Release of Mesotelencephalic Dopamine Following Clozapine and Other Antipsychotic Drugs. Prog. Neuropsychopharmacol. Biol. Psychiatry 1990, 14, S51-S57.
63. Li, X. M.; Perry, K. W.; Wong, D. T.; Bymaster, F. P. Olanzapine Increases In Vivo Dopamine and Norepinephrine Release in Rat Prefrontal Cortex, Nucleus Accumbens and Striatum. Psychopharmacology 1998, 136, 153-161.
64. Ahlenius, S.; Hillegaart, V. Involvement of Extrapyramidal Motor Mechanisms in the Suppression of Locomotor Activity by Antipsychotic Drugs: A Comparison Between the Effects Produced by Pre- and Postsynaptic Inhibition of Dopaminergic Neurotransmission. Pharmacol. Biochem. Behav. 1986, 24, 1409-1415.
65. Elsworth, J. D.; Roth, R. H. Dopamine Synthesis, Uptake, Metabolism, and Receptors: Relevance to Gene Therapy of Parkinson's Disease. Exp. Neurol. 1997, 144, 4-9.
66. Westerink, B. H.; Kawahara, Y.; De Boer, P.; Geels, C.; De Vries, J. B.; Wik Van Kalkeren, A.; Van Vliet, B.; Kruse, C. G.; Long, S. K. Antipsychotic Drugs Classified by Their Effects on the Release of Dopamine and Noradrenaline in the Prefrontal Cortex and Striatum. Eur. J. Pharmacol. 2001, 412, 127-138.
67. Squires, R. F.; Saederup, E. A Review of Evidence for GABAergic Predominance/Glutamatergic Deficit as a Common Etiological Factor in Both Schizophrenia and Affective Psychoses: More Support for a Continuum Hypothesis of "Functional" Psychosis. Neurochem. Res. 1991, 16, 1099-1111.
68. A Receptors. Neurochem. Res. 1997, 22, 151-162.
69. Ross, R. J.; Waszczak, B. L.; Lee, E. K.; Walters, J. R. Effects of Benzodiazepines on Single-Unit Activity in the Substantia Nigra Pars Reticulata. Life Sci. 1982, 31, 1025-1035.
70. Zetterstrom, T.; Fillenz, M. Local Administration of Flurazepam Has Different Effects on Dopamine Release in Striatum and Nucleus Accumbens: A Microdialysis Study. Neuropharmacology 1990, 29, 129-134.
71. Invernizzi, R.; Pozzi, L.; Samanin, R. Release of Dopamine Is Reduced by Diazepam More in the Nucleus Accumbens Than in the Caudate Nucleus of Conscious Rats. Neuropharmacology 1991, 30, 575-578.
72. Finlay, J. M.; Damsma, G.; Fibiger, H. C. BenzodiazepineInduced Decreases in the Extracellular Concentration of Dopamine in the Nucleus Accumbens after Acute and Repeated Administration. Psychopharmacology 1992, 106, 202-208.
73. A Receptor Modulators. J. Pharmacol. Exp. Ther. 1995, 273, 241-247.
74. Tam, S. Y.; Roth, R. H. Selective Increases in Dopamine Metabolism in the Prefrontal Cortex by the Anxiogenic β-Carboline FG 7142. Biochem. Pharmacol. 1985, 34, 1595-1598.
75. Dazzi, L.; Spiga, F.; Pira, L.; Ladu, S.; Vacca, G.; Rivano, A.; Jentsch, J. D.; Biggio, G. Inhibition of Stress- or Anxiogenic-Drug-Induced Increases in Dopamine Release in the Rat Prefrontal Cortex by Long-Term Treatment with Antidepressant Drugs. J. Neurochem. 2001, 76, 1212-1220.
76. Hutson, P. H.; Barton, C. L. L-701,324, a Glycine/NMDA Receptor Antagonist, Blocks the Increase of Cortical Dopamine Metabolism by Stress and DMCM. Eur. J. Pharmacol. 1997, 326, 127-132.
77. Zhou, L.; Zhang, Y. Samarium(II) Iodide Induced Reductive Coupling of Nitriles with Nitro-Compounds. J. Chem. Soc., Perkin Trans. 1998, 1, 2899-2902.
78. Paxinos, G.; Watson, C. The Rat Brain in Stereotaxic Coordinates; Academic Press: London, 1982.
79. Dazzi, L.; Serra, M.; Porceddu, M. L.; Sanna, A.; Chessa, M. F.; Biggio, G. Enhancement of Basal and Pentylenetetrazol (PTZ)-Stimulated Dopamine Release in the Brain of Freely Moving Rats by PTZ-Induced Kindling. Synapse 1997, 26, 351-358.
80. A Receptor by Loreclezole, An Anticonvulsant Drug with Selectivity for the β-Sub-unit. Neuropharmacology 1997, 35, 1753-1760.